Your session is about to expire
← Back to Search
Blinatumomab + Autologous Stem Cell Transplantation for Diffuse Large B-Cell Lymphoma
Study Summary
This trial will test whether the addition of the drug blinatumomab to standard care after stem cell transplant improves outcomes for patients with DLBCL.
- Non-Hodgkin's Lymphoma
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You have a history of serious brain-related conditions such as seizures, stroke, dementia, or Parkinson's disease.You have had a stem cell transplant in the past.You are currently pregnant or breastfeeding.You do not have any significant brain-related conditions like seizures, paralysis, speech problems, stroke, severe head injuries, memory loss, or mental illness.You can participate in the study even if you have a large tumor, but you cannot receive radiation therapy until 30 days after the study drug (blinatumomab) is finished.You have another cancer that needs to be treated at the same time.
- Group 1: ASCT + BEAM + Blinatumomab
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
How many participants are involved in this clinical investigation?
"At this juncture, there is no recruitment for this trial. It was initially posted on the 1st of August 2017 and has been updated most recently on May 4th 2022. For individuals seeking other studies, 1776 clinical trials are presently enrolling patients with lymphoma large b-cell diffuse and 599 investigations which require an Autologous stem cell transplant also have open enrolment requirements."
Are there any vacancies left for the clinical trial?
"According to clinicaltrials.gov, the initial post of this trial was on August 1st 2017 and its most recent update occurred on May 4th 2022. Consequently, it is not currently accepting any new patients; however, 2375 other trials are still actively recruiting participants."
What diseases is Autologous stem cell transplant typically employed to address?
"Autologous stem cell transplant is a therapeutic approach used to treat hematopoietic cells and various other types of cancer such as merkel cell, meningeal leukemia, and prostate."
Is Autologous stem cell transplantation a safe medical procedure for people?
"Given the limited data regarding Autologous stem cell transplant's safety and efficacy, our team at Power rated this therapy with a score of 1."
Share this study with friends
Copy Link
Messenger